US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

BMY Bristol Myers Squibb Co

55.91

0.00 (0.00%)

Pre Mercado

Última actualización: 03:24:11

Retrasado por 15 minutos

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

Both Shuttle Pharmaceuticals (Nasdaq:SHPH) and Northwest Biotherapeutics

To read the full story on AllPennyStocks.com, click here.

Bristol Myers Squibb (NYSE:BMY)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025

Haga Click aquí para más Gráficas Bristol Myers Squibb.

Bristol Myers Squibb (NYSE:BMY)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025

Haga Click aquí para más Gráficas Bristol Myers Squibb.

Noticias sobre Bristol Myers Squibb Co BMY

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments
Lunes 13 de Enero 2025 (3 días hace) • AllPennyStocks.com

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
Lunes 13 de Enero 2025 (3 días hace) • GlobeNewswire Inc.

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
Viernes 3 de Enero 2025 (2 semanas hace) • Business Wire

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
Viernes 27 de Diciembre 2024 (3 semanas hace) • Business Wire

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
Lunes 23 de Diciembre 2024 (3 semanas hace) • Business Wire

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Lunes 23 de Diciembre 2024 (3 semanas hace) • Business Wire

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
Jueves 19 de Diciembre 2024 (4 semanas hace) • Business Wire

Bristol Myers Squibb Announces Dividend Increase
Miércoles 11 de Diciembre 2024 (1 mes hace) • Business Wire

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
Lunes 9 de Diciembre 2024 (1 mes hace) • Business Wire

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference
Martes 26 de Noviembre 2024 (2 meses hace) • Business Wire

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Martes 19 de Noviembre 2024 (2 meses hace) • Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Viernes 15 de Noviembre 2024 (2 meses hace) • Business Wire

Más de Bristol Myers Squibb Co Artículos de Noticias

BNP Paribas (QX)

Gold vs US Dollar

Invesco QQQ Trust Series 1

Health Care Select Sector

Verizon Communications

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones